Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Baqiyatallah University of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Previous 3 dose hepatitis B vaccination
- Negative HBc Ab
- Negative HBs Ag
- HBs Ab less than 10 in ELIZA
Exclusion Criteria:
- positive serologic evidence of Hepatitis B infection
- Chronic use of Atorvastatin
- Immunosuppressive Disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Atorvastatin
will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
|
one 40 mg Atorvastatin tablet orally per day for 10 days
|
|
Placebo Comparator: Placebo
will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
|
one Placebo tablet orally per day for 10 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in serum HBsAb level
Time Frame: 1 month after vaccination
|
HBsAb level in serum measurement with quantitative ELIZA method
|
1 month after vaccination
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
IL-4 level in WBC culture
Time Frame: 1 month after vaccination
|
IL-4 level measurement with polymerase chain reaction method
|
1 month after vaccination
|
|
IL 17 level in WBC culture
Time Frame: 1 month after vaccination
|
IL 17 level measurement with polymerase chain reaction method
|
1 month after vaccination
|
|
TGF-beta level in WBC culture
Time Frame: 1 month after vaccination
|
TGF-beta level measurement with polymerase chain reaction method
|
1 month after vaccination
|
|
IFN-gamma level in WBC culture
Time Frame: 1 month after vaccination
|
IFN-gamma level measurement with polymerase chain reaction method
|
1 month after vaccination
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Nematollah Jonaidi Jafari, MD, Baqiyatallah University of Medical Sciencesc
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
Other Study ID Numbers
Other Study ID Numbers
- behdasht-90-6-16
- IRCT201109147556N1 (Registry Identifier: Iranian Registry of Clinical Trials)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.